Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3387 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-01

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite the rise in prescriptions for direct oral anticoagulants,Vitamin K antagonists(VKA) remains the most prescribed treatment for treating and preventing long-term thromboembolic events. They remain the most important drugs of iatrogenic accidents despite the means deployed by the health authorities. The balance of the patients under VKA can be appreciated thanks to the time spent in the therapeutic zone or TTR which is correlated with the risk of occurrence of haemorrhagic or thrombotic events.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anticoagulant Clinics and Vitamin K Antagonists

NCT00966290

Blood Coagulation Disorders

COMPLETED PHASE4

Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department

NCT06692504

Hemorrhage Thrombosis Anticoagulant Therapy +1 more

RECRUITING

Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding.

NCT01727453

Acute Gastrointestinal Bleeding

COMPLETED PHASE4

Long-term Outcome After Heparin and Edoxaban Versus Heparin Plus Vit K Antagonists for Acute DVT and PE

NCT03757481

Post Thrombotic Syndrome Deep Vein Thrombosis Chronic Thromboembolic Pulmonary Hypertension

COMPLETED NA

Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme

NCT01809015

Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use Atrial Fibrillation Venous Thromboembolism

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite the rise in prescriptions for direct oral anticoagulants, Vitamin K antagonists (VKA) remains the most prescribed treatment for treating and preventing long-term thromboembolic events. They remain the most important drugs of iatrogenic accidents despite the means deployed by the health authorities. The balance of the patients under VKA can be appreciated thanks to the time spent in the therapeutic zone or TTR which is correlated with the risk of occurrence of haemorrhagic or thrombotic events.

The management of VKA in France seems hardly comparable to that of the neighboring countries in front of:

* A TTR estimated at 60%.
* Majority management of anticoagulant treatments by general practitioners.
* The weak development of clinics anticoagulants.
* The takeoff of direct oral anticoagulant prescriptions.
* Preponderance of fluindione prescriptions among the various oral anticoagulants.

It therefore seems interesting to study a cohort of French patients under VKA. Through the calculation of the TTR, the investigators will be able to draw a picture of the balance of the anticoagulant treatment and try to identify factors that can influence it.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient treated with VKA.
* Realization of INR in one of the labs of the territory of LaboSud Oc biology between 1 September 2015 and 13 January 2016.

Exclusion Criteria

* Less than 3 INR during the data collection period (TTR calculation not possible).
* Time greater than 56 days between two INRs (calculation of the invalid TTR).
* Interrupted treatment (calculation of invalid TTR).
* Lack of information about the patient

Eligible Sex

Accepts Healthy Volunteers

No